News
Elara had already factored in approximately $20 million in revenue from gAbraxane in the US for FY26. While 3–4 generic ...
Bristol Myers Squibb Co. closed 20.32% short of its 52-week high of $63.33, which the company achieved on March 11th.
With data as of April 9, 2025, we examine if Bristol-Myers Squibb Company(BMY) is consistently building momentum based on ...
Bristol-Myers Squibb Company (BMY) is currently at $50.78, down $2.96 or 5.5% --Would be lowest close since Sept. 26, 2024, when it closed at $50.12 --On pace for largest percent decrease since April ...
Bearish flow noted in Bristol Myers ( BMY) Squibb with 7,624 puts trading, or 1.4x expected. Most active are 5/2 weekly 50 puts and May-25 65 calls, with total volume in those strikes near 5,500 ...
The threat of tariffs has put the pharma industry through the wringer this week. On Wednesday, a week after instituting widespread tariffs and a day after promising that “major” tariffs were headed ...
To name a few, Johnson & Johnson, Merck & Co., and Bristol Myers Squibb are all top NJ-based industry names with broad export footprint in China.
21h
Arabian Post on MSNAI Firms Reshaping Drug Discovery LandscapeArtificial intelligence is increasingly becoming a cornerstone in pharmaceutical research, with numerous companies leveraging advanced algorithms to expedite drug discovery and development. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results